GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » ROA %

Lavipharm (ATH:LAVI) ROA % : -0.60% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Lavipharm ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Lavipharm's annualized Net Income for the quarter that ended in Dec. 2023 was €-0.69 Mil. Lavipharm's average Total Assets over the quarter that ended in Dec. 2023 was €116.25 Mil. Therefore, Lavipharm's annualized ROA % for the quarter that ended in Dec. 2023 was -0.60%.

The historical rank and industry rank for Lavipharm's ROA % or its related term are showing as below:

ATH:LAVI' s ROA % Range Over the Past 10 Years
Min: 1   Med: 3.34   Max: 28.85
Current: 1.62

During the past 7 years, Lavipharm's highest ROA % was 28.85%. The lowest was 1.00%. And the median was 3.34%.

ATH:LAVI's ROA % is ranked better than
50.69% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.36 vs ATH:LAVI: 1.62

Lavipharm ROA % Historical Data

The historical data trend for Lavipharm's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm ROA % Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial 11.67 4.19 3.34 1.00 1.63

Lavipharm Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.31 7.06 -2.52 3.83 -0.60

Competitive Comparison of Lavipharm's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lavipharm's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lavipharm's ROA % distribution charts can be found below:

* The bar in red indicates where Lavipharm's ROA % falls into.



Lavipharm ROA % Calculation

Lavipharm's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=1.871/( (114.168+114.786)/ 2 )
=1.871/114.477
=1.63 %

Lavipharm's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-0.694/( (117.718+114.786)/ 2 )
=-0.694/116.252
=-0.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Lavipharm  (ATH:LAVI) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-0.694/116.252
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.694 / 42.948)*(42.948 / 116.252)
=Net Margin %*Asset Turnover
=-1.62 %*0.3694
=-0.60 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Lavipharm ROA % Related Terms

Thank you for viewing the detailed overview of Lavipharm's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lavipharm (ATH:LAVI) Business Description

Traded in Other Exchanges
Address
Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes innovative, safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm (ATH:LAVI) Headlines

No Headlines